ASX Announcement ASX : ENP 28 October 2026 Quarterly Activities Report & Appendix 4C: September 2026 • TRP-8803 Phase 2 Binge Eating Disorder (BED) study delivers highly encouraging clinical results • Results included 100% of BED patients achieving clinically meaningful improvement and 50%...
Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix is reading this filing.
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study
- All Patients Improve, 50% Achieve 12-Week BED Remission
- Appendix 4E and 2026 Annual Report
- Entropy Advances TRP-8803 to US Phase 2 in Depression
- TRP 8803 manufacturing secured for Phase 2/3 advancement
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics